Precision therapies are often approved based on small trials, in specialized settings, and using biomarkers as endpoints. Thus, despite their potential high cost, the evidence of value is lacking which makes real-world evidence crucial.
Other featured articles
USC Study Finds When Medicare Chips in for Hepatitis C Treatment for Medicaid Patients, Everyone Wins
A Medicaid-Medicare partnership could cover lifesaving hepatitis C medications — and still save $1 to $1.1 billion over 25 years
FDA’s Approval of Aducanumab Paves the Way for ‘More Momentous’ Alzheimer’s Breakthroughs
New in STAT, Dana Goldman and Darius Lakdawalla discuss how the FDA’s recent approval of the first disease modifying therapy aducanumab against Alzheimer’s disease will pave the way for bigger breakthrough.
Impacts of First-in-Class Drug Approvals on Future in-Class Innovation
Some claim that FDA approval of drugs with uncertain efficacy today will slow future innovation. In fact, the relationship is much more complex.
Roybal Fellow Sparks Winning Nudge to Increase Vaccine Uptake
Jehan Sparks helped design the top-performing “nudge” which resulted in an 11% increase in the rate of flu shot vaccinations.
The Leonard D. Schaeffer Center for Health Policy & Economics, one of the nation’s premier policy centers, measurably improves value in health through evidence-based policy solutions, research excellence, and private- and public-sector engagement.about
More from Schaeffer
Our Policy Areas
From aging to drug pricing to health disparities, Schaeffer Center experts are advancing research to inform policy. Learn about the areas we work in.Learn More
Work & Study at USC
The Schaeffer Center develops innovators for positions in higher education, research, government and healthcare through degree programs and postgraduate opportunities.Learn More
Using Precision Medicine in Clinical PracticeDespite its promise and multimillion dollar federal investments, the development and implementation of precision medicine in routine clinical care continues to be slow. How can we translate theory into practice?Date of event:
Developing Effective Payment and Reimbursement ModelsTargeted therapies can come with significant costs. But successful use of personalized medicine can also result in better healthcare outcomes and reduced long-term costs over time. Given this, how we pay for these therapies may require new approaches and models.Date of event: